Merck: MK-4208, Formerly TERN-701, Is Novel Investigational Oral Allosteric BCR::ABL1 Tyrosine Kinase Inhibitor Recently Granted BTD by FDA for Treatment of Certain Adults With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia >MRK

Dow Jones2026/08/04 10:30

By:Dow Jones

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Hyundai Mobis Target Price Cut to KRW470,000 From KRW560,000 by Nomura >012330.SE

Dow Jones•2026/09/16 02:29

A New Crypto Wave Is Brewing: 7 Top 100x Cryptos Nobody Wants to Miss

TimesTabloid•2026/09/16 01:18

Only 3 Altcoins Pass the Relative Strength Test, For Now

BeInCrypto•2026/09/16 01:18

AVAX Price Eyes $15 as Korean Won Stablecoin Goes Onchain

Coinpedia•2026/09/16 00:30